Dr. Barlogie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One Gustave L. Levy Place
Box 1185
New York, NY 10029Phone+1 212-241-7873Fax+1 212-241-8608
Education & Training
- University of Heidelberg Faculty of MedicineClass of 1965
Certifications & Licensure
- AR State Medical License 1989 - 2022
- NY State Medical License 2016 - 2022
- TX State Medical License 1976 - 2005
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma Start of enrollment: 1994 Jan 01
- UARK 2003-33, Total Therapy III Start of enrollment: 2004 Jan 01
- Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide Start of enrollment: 1998 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 198 citationsRenal failure in multiple myeloma. Pathogenesis and prognostic implications.Raymond Alexanian, Bart Barlogie, Dennis O. Dixon
Archives of Internal Medicine. 1990-08-01 - 215 citationsResults of autologous stem cell transplant in multiple myeloma patients with renal failure.Ashraf Badros, Bart Barlogie, Eric R. Siegel, Jennifer Roberts, Candi Langmaid
British Journal of Haematology. 2001-09-01 - 773 citationsFrequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaChristina M. Annunziata, R. Eric Davis, Yulia N. Demchenko, William T. Bellamy, Ana Gabrea
Cancer Cell. 2007-08-14
Journal Articles
- Mesenchymal Stem Cells Gene Signature in High‐Risk Myeloma Bone Marrow Linked to Suppression of Distinct IGFBP2‐Expressing Small AdipocytesBart Barlogie, Sharmilan Thanendrarajan, Carolina Schinke, British Journal of Haematology
Abstracts/Posters
- Long-Term Outcome of Total Therapy Regimens: Impact of Molecular SubgroupsBart Barlogie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...Bart Barlogie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple MyelomaBart Barlogie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- The Mutational Landscape of Primary Plasma Cell Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- MCRT Webcast: Immunotherapy - St. Louis MCRT Part 1February 11th, 2022
- Minimal Residual Disease Negativity by Next-Generation Flow Cytometry Is Associated with Improved Organ Response in AL AmyloidosisFebruary 16th, 2021
- Introduction the Combination of Bortezomib, Lenalidomide, AndMay 11th, 2020
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: